RxDoctor Payments Data

Indumathi Christopher, MD

Geriatric Medicine · Crestview, FLNPI 1467453613

Payments from drug & device makers

$236in general payments, 2019–2025

Across 16 payments — averaging $14.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$62
  • Lilly USA, LLC$29
  • Abbott$27
  • Amgen$27
  • Otsuka America Pharmaceutical, Inc.$22
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$18
  • plus $52 from 4 others

What the payments were for

  • Food & beverage$236100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$236 in reported general payments places this provider in the 45th percentile of 305 geriatric medicine providers in Florida.

See all geriatric medicine providers in Florida

Medicare billing

Part B allowed, 2024
$921,565
Medicare patients
1,017
Services billed
16,609

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide337$349,210
JardianceEmpagliflozin360$279,765
EliquisApixaban480$278,242
OzempicSemaglutide76$129,747
Trelegy ElliptaFluticasone/Umeclidin/Vilanter102$106,237
IngrezzaValbenazine Tosylate22$101,596
RexultiBrexpiprazole96$99,106
MyrbetriqMirabegron243$87,791
Soliqua 100-33Insulin Glargine/Lixisenatide42$63,396
EntrestoSacubitril/Valsartan105$59,763
XareltoRivaroxaban73$54,388
BiktarvyBictegrav/Emtricit/Tenofov Ala13$48,625
TrulicityDulaglutide42$46,144
DovatoDolutegravir Sodium/Lamivudine13$44,830
Tresiba Flextouch U-100Insulin Degludec50$34,381

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$29$395,354379 claims
PfizerEliquis$11$278,242480 claims
Novo NordiskOzempic$62$129,74776 claims
GSKTrelegy Ellipta, Breo Ellipta$16$120,779135 claims
Otsuka America Pharmaceutical, Inc.Rexulti$22$99,10696 claims
Johnson & JohnsonXarelto$12$54,38873 claims
AstraZenecaFarxiga, Brilinta, Breztri Aerosphere$13$52,30777 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 305 geriatric medicine providers in Florida.

Other geriatric medicine in Crestview

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →